COST EVALUATION IN ADULT ICU: A TWO-YEAR STUDY IN A GREEK STATE HOSPITAL

Dimitrios Kosmidis¹, Sotiria Koutsouki², Klairi Lampiri³, Eva Ottlia Nagy⁴, George Anastassopoulos⁵, Vasilios Papaioannou⁶, Ioannis Pneumatikos⁶

1. RN, PhD, General Hospital of Kavala, Greece
2. RN, General Hospital of Kavala, Greece
3. MD, Cardiologist, General Hospital of Kavala, Greece
4. MD, Anesthesiologist, ICU Director, General Hospital of Kavala, Greece
5. PhD, Medical Informatics Laboratory, Democritus University of Thrace, Alexandroupolis, Greece
6. PhD, Democritus University of Thrace, Alexandroupolis University Hospital, ICU Director, Greece

Abstract

Background: During the last decades the combination of international economic and healthcare crisis has led to pressure on healthcare systems and has made financial evaluations particularly important.

Aim: To measure the total cost in ICUs, to analyze its components, and their changes during the study period.

Method and Material: All cost components in four cost categories (direct-variable, direct-fixed, indirect-variable, and indirect-fixed) of all patients admitted in a 6-bed mixed type adult ICU in a general (non-university) hospital of northern Greece in two consecutive periods, with total duration 2 years was measured. The direct-variable cost (medications, consumables, and diagnostic tests) was assessed with bottom-up (micro-costing) method while for the cost components of rest three categories the top-down (attributable costing) was used.

Results: In a 331 patients’ sample with 2823 total patient days, the sum cost was 2,417,788€ (1,370,420€ and 1,047,368€ in 1st and 2nd period respectively). The direct variable cost was 897,866.07€ (37.14%), the direct-fixed 1,049,068.6€ (43.39%), the indirect-variable 45,210.6€ (1.87%), and the indirect-fixed 425,643.0€ (17.60%). The mean daily cost per patient was 835.62€ and 885.35€, and the total cost per patient was 7,967.6€ and 6,587.2€ in the two periods of study respectively. The total cost of all non-survivors’ patients (N=85, 25.7%) was 595,009.1€ and the efficiency cost per survivor 9,828.4€. The mean daily cost and the total cost per survivor was 840.8€ and 7,409.7€ while for non-survivors was κα 908.4€ and 7,000.1€ respectively. During the second study period, a reduction in total costs was observed and especially in direct-variable category attributed mainly to the prices of medicines consumables, and staff gradual costs reductions.

Conclusions: Changes in cost categories vary over time due to social and financial factors while the variables as the ICU environment or patient’s characteristics as severity of disease are the main cost drivers. Monitoring and recording of cost components variance would help with valuable information to healthcare managers, doctors, or nursing leaders. Extending this study with a multicenter to more ICUs could provide clearer conclusions about cost variability.

Keywords: Cost evaluation, economic analysis, intensive care unit.

Corresponding Author: Dimitrios Kosmidis, General Hospital of Kavala, St Sillas P.C. 65500 KAVALA, Greece, Fax Number: +30 2591047322, Phone Number (mob): +30 6945198861, Email: kosmidis_gr@yahoo.gr

Cite as: Kosmidis, D., Koutsouki, S., Lampiri, K., Nagy, EO, Anastassopoulos, G., Papaioannou, V., Pneumatikos, I. (2021). Cost evaluation in adult ICU: a two-year study in a Greek state hospital. Health and Research Journal, 7(1), 39-54. https://ejournals.epublishing.ekt.gr/index.php/HealthResJ
INTRODUCTION

Many healthcare professionals have the belief that they should not be interested in economics and financial management, without though realizing that they already actively participating in the financial healthcare system, since the role of patient care is closely associated with economic powers such as cost, revenue, and profit. Doctor and nursing leaders at Intensive Care Units (ICUs) are increasingly obligated to know, manage, and prepare budget and business plans to secure their sources required for providing and improving care in their units.1 Patient care in (ICUs) is becoming increasingly expensive yet; cost analysis studies of ICUs are rare.2 In previous decades costs in the health sector and particular in ICUs have shown rates greater than inflation, making the cost of these services unsustainable for many countries. In Greece from 2010 - 2015 due to the economic crisis in-situ, health spending shrank by 1.2% GDP (i.e., from 9.56% to 8.38%), while public funding for health spending fell by 6.2 billion Euros (i.e. from 14.9 to 8.7 billion).3 The cost of intensive care is now 'substantial' not only for the state budgets, but also for the citizens who are ultimately indirectly carrying the corresponding financial burden via taxes for this expenditure. As with an increasing aging population, resources for caring for patients in need of intensive care will become increasingly scarce.

In addition, the survivors of intensive care, will subsequently present with increased co-morbidity and disability, i.e. continuing to use high-rate healthcare resources.4 On the other hand, many patients who have little or minimal life expectancy are still admitted to an ICU and thus, 'consume' significant resources, burdening further overall operating costs.5 Inevitably, questions arise as to whether society is prepared to pay for these costs and whether this high cost of ICU care is 'worth the price'. Such dilemmas are being raised more often due to increasing pressure from hospitals to measure and justify their costs, particularly for care with special reference to cost-quality and cost-effectiveness.6 Analytical methods for calculating total costs, although useful, are often time-consuming and laborious, and precise data are often not available.7,8 Alternatively, cost estimates are performed with gross estimates or are attributed by representative measures such as on the basis of Diagnostic Related Groups (DRGs)9,10 length of stay11, disease severity12 or nursing workload.13 These methods, while dealing with a certain number of difficulties and representing cost to a semi-satisfactory extent do not, however, represent actual costing which requires greater precision.

In an analysis of cost factors, a two-tier classification is customarily used, i.e., fixed, and variable costs. Fixed costs are those that remain relatively unchanged, i.e., they are independent of the number of patients (staff salaries, capital depreciation, maintenance costs, etc.) while the variable costs are those that change depending on the number of patients and the procedures performed on them (medicines, materials, diagnostic tests, etc.). An additional classification proposed is that of direct and indirect costs. The direct cost is that of the patient's proper care and depends on the amount on the patient per se, and the indirect cost is the administrative or fixed costs related to all other fixed expenditures.7,13 The combination of these two gives rise to four different cost categories that can be measured and analyzed separately.

In addition, two main approaches have been proposed for detailed measurement of the overall costs of an ICU: the ‘top down’ or ‘attributable costing’ and the ‘bottom-up’ or micro-costing approach. The top-down method is approximate, i.e., costs are recorded overall and then distributed proportionally per patient, usually based on his or her length of hospitalization.13 It is understandable that other costs such as the fixed costs of an ICU or staffing costs are almost impossible to measure per patient and therefore in such cases the top-down method is more appropriate.

The bottom-up method records the cost of each material or activity and then adds-up to the overall cost (usually per patient). The bottom-up method, although it can only be applied to the calculation of certain cost elements (e.g. medicines, materials and patient diagnostics), is a precision tool and is an option for specific financial assessments.7,8 Tan et al. proposed a mixed cost-accounting approach, i.e. the combination of the two above methods for cost calculation in seven ICUs in four
European countries (Germany, Italy, the Netherlands and the United Kingdom). In accordance with this technique, direct-variable costs can be measured using the micro-costing method and for all other categories the costing methodology. This mixed approach appears to be gaining ground in the literature as many cost-accounting analyzes are increasingly turning to this practice.

Nevertheless, to date there are insufficient cost analytical data for ICUs, and those available are based either on indirect approaches, using a relatively short time measurement, or on measurements of limited cost categories.

AIM
The aim of the present study was to measure the total cost in ICUs, to analyze its components, and their changes during the study periods.

MATERIAL AND METHOD

Design, sample, and study duration
In this study a mixed approach with full and detailed cost data, in a 6-bed ICU non-university state hospital in northern Greece with 399 total beds, was used. The type and design of the study was a prospective observational study with a target population of all type adult ICU patients (non-cardiology) and a sample of all adult patients admitted in ICU. The duration of data collection was two consecutive years i.e., 2014 - 2016 (from 1/7/2014 to 30/6/2016) and for analysis it was divided into two corresponding periods: from 1/7/2014 to 30/6/2015 (1st period) and from 1/7/2015 to 30/6/2016 (2nd period).

Cost calculation categories and modalities
During the two study periods, all relevant economic data from successive admissions into the ICU were recorded, with a breakdown of four different cost categories as follows:

(a) Direct-Variable cost, which is concerned with expenses concerning direct patient care and is dependent on the number of ICU inpatients. This category included all expenditure on health equipment (consumables), diagnostic tests (imaging, microbiology, hematology, and biochemical laboratory tests) and medication (drugs and fluids) per patient.

(b) Direct-Fixed cost, i.e., costs relating to the direct care of patients, which are independent of the number of patients treated. This category included the gross costs of staff remuneration (doctors, nurses, and other ICU staff), the costs of purchasing new, and the maintenance of existing medical equipment and training of ICU staff. For the costs of training, these were calculated indirectly (by the days of absence of the staff on educational leave) and were not included in the final totals as these costs were included in the salary received by the staff without working on the days of the training leave.

(c) Indirect - variable cost, i.e. costs not related to the direct care of patients but dependent on the number of patients treated. This category included the various ICU common-use materials (reagents, cleaning materials, clothing, technical materials, maintenance of common equipment and stationery).

(d) Indirect Fixed cost, i.e., costs not related to the direct care of patients and independent of the number of patients treated. In this category, the individual cost components were calculated using the analytical method of accounting by an employee at the hospital, specialized in this area. This category included inter alia the proportional allocation of costs of other sections and costs borne by the ICU, the depreciation of fixed capital (equipment) of the ICU, the proportional allocation of costs of the hospital support services (administrative, technical, hospital care, etc.), heating, maintenance, and cleanliness of premises (building infrastructure), energy consumption and water use. Also, some of these (e.g., cleaning, electricity, water consumption, etc.) were calculated based on the ratio of the ICU square meters (2.39%) to the square meters of the whole hospital.

In the first category (direct-variable cost) the calculation was made using the bottom-up method, i.e., the analytical recording of all individual cost components for each individual patient (medication, materials, diagnostic tests, etc.). In the remaining three categories (direct-fixed, indirect-variable, and indirect-fixed costs), calculations were made per cost component in detail but the total resulting amounts were allocated to patients according to their treatment days.

For all the individual cost components and the above categories, the total amounts, the corresponding amounts per ICU
day and per patient, were calculated for the two periods and in total. In addition, the efficiency index per survivor (effective cost per survivor: ECPS) corresponding to the cost of all patients (cost of treating patients) and the indirect-variable cost of the surviving and non-surviving patients were also calculated.

**Log Tool**

A relational electronic database designed specifically for the purpose of this study was used to analyze all economic data. This database ('Care Unit Quality Management Registry' or 'ICU-QMR') also included patient demographics and analytical clinical data on medical and nursing procedures. In order to monitor the variance of ICU costs, all economic parameters by cost category, the recording of which was based on the above-described mixed approach, were included in detail. The application included, among other things, the ability to directly access the view of multiple aggregated charts related to the time variance of all economic parameters.16

**RESULTS**

Out of a total 338 patients enrolled during the study in the ICU, seven cases (extravagant inflows of very short duration of minor patients) were excluded and the final analysis sample was 331 adult (>= 18 years) patients (172 and 159 in period 1 and 2, respectively). The total ICU time (days) were 2823 (1640 and 1183 (in periods 1 and 2, respectively). Table 1 and 2 show the main sample characteristics.

The total cost of all categories in the two years was 2,417,788€ (1,370,420€ and 1,047,368€ in period 1 and period 2 respectively). The average total cost per patient was 7,304€ and the average daily cost of 856€. The total direct-variable cost was 897,866€ or 2,712€ average cost per patient or 318€ per ICU day. Direct-variable costs accounted for 41.7% (period 1) to 31.1% (period 2) of total costs. The total direct-fixed cost was 1,049,069€. The average cost per patient was 3,169€ or 371€ per ICU day. Direct-fixed costs accounted for 40.4% (period 1) to 47.3% (period 2) of total costs. The indirect variable cost was 45,210€. The average cost per patient was 137€ or 16€ per ICU patient day. Indirect variable costs accounted for 1.7% (period 1) to 2.1% (period 2) of total costs. The indirect-fixed cost was 425,643€. The total average cost per patient was 1,286€ or 150€ per ICU patient day, accounting for 16.2% (period 1) to 19.4% (period 2) of the total ICU costs (Table 3).

In surviving patients (N=246) APACHE II Score was 18.28±7.36, the mean LOS was 8.81±10.15 days and the total cost of all categories throughout the study was 182,279.6€ or 7,409.7€ per patient or 840.8€ per ICU day. In the patients who died (N=85) APACHE II Score was 25.54±6.98, the mean ICU time was 7.71±9.47 days, and the total cost was 595,009.1€ or 7,000.1€ per patient or 908.4€ per ICU day. The average cost of efficiency per surviving patient was 9,828.4€. Finally, the total direct-variable cost in surviving patients was 655,513€ or 2,664.7€ per patient or €302.4 per ICU day, whereas the cost of non survivors was 242,352.7€ or 2,851.2€ per patient or 370.0€ per ICU patient day.

The tables below show the totals (Table 4), the mean daily and the mean total cost per patient (Table 5) for each combined category in 2 study periods.

The percentages of patients who developed multi-resistant micros (Carbapenem-Resistant Acinetobacter baumannii - CRAB, Klebsiella pneumoniae, Carbapenem-Resistant Pseudomonas aeruginosa - CRPA, Methicillin-Resistant Staphylococcus aureus - MRSA, και Vancomycin-Resistant Enterococcus - VRE) during the ICU stay, varied between the first (11.04%, N=19) and the second study-period (10.06%, N=16). This factor was associated (p<0.05) with the mean ICU stay (22.80±14.6 versus 6.84±7.72 days), the mean MV duration (14.82±9.4 versus 4.56±5.94 days) and all other cost components. The average total direct-variable cost per patient with multi-resistant microbes was 8230.8€ versus 2,060.1€ per patient without development of multi-resistant microbes. The cost of consumables, medicines, laboratory, and imaging tests in patients with multi-resistant microbes was 2120.8€ versus 2,060.1€ per patient without development of multi-resistant microbes. The cost of consumables, medicines, laboratory, and imaging tests in patients with multi-resistant microbes was 2120.8€ versus 2,060.1€ per patient without development of multi-resistant microbes. The cost of consumables, medicines, laboratory, and imaging tests in patients with multi-resistant microbes was 2120.8€ versus 2,060.1€ per patient without development of multi-resistant microbes. The cost of consumables, medicines, laboratory, and imaging tests in patients with multi-resistant microbes was 2120.8€ versus 2,060.1€ per patient without development of multi-resistant microbes.
second study-period, (Table 6) resulted in an absolute reduction in total costs of 13.46% (from 547,293.0€ to 473,594.4€). However, due to the decrease in the number of total ICU days from the first to the second study-period (-27.9%), expenditure per ICU day for staff remuneration increased by 19.9% (from 333.7€ in the first to 400.3€ to the second study-period). Thus, while the overall average cost per patient fell from 7,967.6€ to 6,587.2€ from the first to the second study-period, the average daily cost per patient increased from 835.62€ to 885.35€. In other words, although there was a reduction in the cost due to the reduction in staff number, the cost increase per ICU day due to LOS reduction (from 9.53±11.54 to 7.44±7.38 days), was more significant. This increase in the average daily cost per patient, except for a reduction in the mean ICU LOS, can be attributed to the difference in patient severity (APACHE II score: 19.88±7.8 versus 20.56±8.02, p<0.05) as well as those patients who developed multi-resistant infections as reported above.

**DISCUSSION**

The highest cost rates were observed at the direct-variable and direct-fixed costs but differentiated in the two study periods (Graph 1). In period 1, 41.7% ranked direct-variable costs first among the categories with direct-fixed costs followed by 40.4%. This finding is not consistent with the international literature, in which, by a large majority, staff costs usually account for the highest proportion of the costs of all categories.

In the second study period, a reversal of these rates (Graph 1) was observed, the first percent being direct-fixed costs (47.3%) with direct-variable followed by 31.1%. This reversal is mainly due to a reduction in the direct-variable costs (~20.9% per ICU day), consumables (~25.9%) and medicines (~20.4%) and was found to be at a statistically significant level (p<0.05). At the same time, there was a relative increase in the share of total direct-fixed costs (mainly in staff costs). These changes can be explained by the following factors:

First, the economic crisis in Greece, which has obviously gradually brought about both better financial control and lower prices for medicines and consumables. It is well known that since 2010 Greece was under austerity and one of the measures taken to deal with it was to reduce the cost of hospital supplies (pharmaceuticals, medical supplies, orthopedic devices, chemical reagents, etc.). Hospital fees accounted for 68% of the total operating costs of hospitals (excluding salaries) and with measures such as simplifying procedures, commissions, implementing reforms in pharmaceutical policy and horizontal cuts decided by the Ministry of Health, a reduction of around 38.2% was achieved. In the pharmaceutical policy in particular, the promotion of the use of generic medicines in the public health system and policies such as the introduction of a national electronic prescription system, the prescription of the active substance rather than the commercial equivalent, the mandatory 50% rate in the use of generic medicines and the imposition of the limit on the maximum price of generic medicines (up to 60% of the price of labeled medicines) have led to an increase use of generic medicines representing 26% of total pharmaceutical costs in public hospitals in 2011. With similar policies, spending in 2011 on medical supplies, pharmaceutical and chemical reagents fell by 38.5%, 29% and 30.5%, respectively. These policies were continued during the study period, resulting in gradual reductions in the costs of both pharmaceutical and ICU medical materials.

Another reason was the decrease in the mean mechanical ventilation (MV) duration (from 6.31±8.12 during the first, to 4.89±5.74 days in the second study-period, respectively). However, the percentage of patients’ time in MV relative to their total ICU LOS between 1st and 2nd (64.9% and 65.7% respectively) did not differ (p>0.05) statistically and the above difference should be attributed to the shorter mean LOS in the second study-period. It is documented in the literature that MV is associated with significantly higher daily costs for patients in the ICU and interventions related to the reduction in MV duration lead to significant reductions in the total patient cost. In addition, it is proven that prolonged LOS in combination with MV predisposes a patient to greater risk of infections and death which also increase costs.

The average total direct-variable cost per patient with multi-resistant microbes was about fourfold greater than per patient...
without development of multi-resistant microbes. These results are confirmed in the international literature. In the study by Jia et al., it was found that the increase in the cost of hospitalization in patients with multi-resistant microbes (6,127.65€ versus 2,274.02€ of the control group) was statistically significant (p<0.01) and was mainly due to additional pharmaceutical costs. In the systematic review of Tansarli et al. it was also found that in 17 of the 24 studies, researchers had reached the same conclusion, i.e. the correlation between multi-resistant microbial infections and increased patient care costs, regardless of the range of micro-organisms, the type of infection, the patient population and healthcare systems.

Although it cannot be confirmed, an impact by the ICU management is likely, as they have gradually shown increasing interest in reducing waste during the study period contributing significantly to the reduction of costs (Hawthorne effect). These results are partly comparable with the international literature. For example, Lefrant et al. (2009) estimated the staff cost rate to be of 43% and the total direct cost of 59%. The average direct cost per patient was 842±521€ while direct-variable costs (staff costs) were 607€ (versus 333.7€ to 412.8€ in the present study) and the indirect-fixed (administrative) costs of 326€ (versus 135€ to 171€ in this study). The above variances can be attributed to the difference in average staff-cost (the difference between the 2009 GDP of France and that of Greece in 2016 was 13,700€) as well as the difference related to staffing mainly of doctors and nurses between the two countries.

The average direct-variable cost (318.1€ in the present study), although it showed a significant downward trend between study periods, (from 348.6€ in the first to 275.7€ in second study-period), is still far from the corresponding cost (130€ per ICU day) in the Lefrant et al. study.

In a similar study by Karabatsou et al. in 138 ICU patients in a Greek hospital in Athens with a LOS of >24 hours, the variable cost was 573.18€ per patient day versus 334.06€ (sum of direct and indirect variable costs) in the present study. These differences may be due to the different methodology (e.g. in this study, all the materials, drugs and tests of all patients enrolled into the ICU were calculated), the mean ICU LOS (8 versus 8.5 days in the present study), patient severity (APACHE II score 18.64±0.61 versus 20.20±7.92 in this study) and other possible factors that cannot easily be determined.

In general, however, it is understood that there has been a gradual reduction in the variable costs due to the factors discussed above, the reduction in the price of medicines and materials for the ICU, but also the reduction in staff remuneration costs. Cost studies in the ICU have traditionally focused on variable on direct-variable costs that differ from one patient to another as they are the costs affected by policies and interventions to reduce the LOS in the ICU. However, it has been reported that up to almost 80% of the cost of an ICU is in fact stable. Direct-variable costs contribute little to the total cost of an ICU and therefore the modification of ICU LOS may not result in significant cost differences. In contrast, it has been reported that greater cost savings can be achieved through changes in fixed costs, such as improved appropriate use of beds or appropriate staffing in the ICU.

In our study, the fixed cost rate reached 66.7% (second study-period) with nursing and medical staff costs being the greatest. The remaining 33.3%, which was the variable cost (second study-period) although not negligible, was relatively low compared to other studies and this can be attributed to the reduced staffing of medical staff, but also to the relatively low salaries in general of hospital staff in Greece.

Regarding indirect-fixed costs, the reduction observed by 8.47% (from 22,233.1€ in the first to 203,409.9€ in the second study-period) can be attributed mostly to the shorter treatment duration since the calculation of these costs was proportional to the patient's LOS and less to the reduction in actual costs. In a similar study in India over the same period, indirect costs accounted for 19.4% of total costs (compared to 19.5% in the present study).

The Efficiency Cost Per Survivor (EPCS) and the financial loss per patient are useful measures to reimburse costs to the ICU. As more resources are spent on non-survivors, the EPCS increases significantly. In the study of Kulkami et al., for example, it was found that cost efficiency could be improved in a group.
of post-operative cancer patients when they were hospitalized in a ward and not in the ICU, concluding that care limits should be set in patients who may have a poor outcome. In our study, the direct-variable daily cost (Table 7) was 22.37% higher in the non survivors than in the survivors. In a corresponding study in the US in 2003-2005 in 572 patients in five ICUs with a total of 88 beds, direct-variable costs represented 20% of total cost, direct-fixed costs 45% and the remaining indirect costs 34% versus 38.3%, 42.6% and 19 1% respectively in this present study (Graph 2). Although the difference in direct-variable costs between the two patient groups was non-statistically significant (p>0.05), the non survivors had higher consumption of medicines and materials (Graph 3), which can be attributed mainly to the higher disease severity when entering the ICU at a statistically significant level (p<0.05). As a result, the average cost per patient day for non survivors was significantly higher. However, the lower average ICU LOS by about one day resulted in reduced costs (directly-fixed and indirectly-fixed costs) and ultimately lower average total costs per non survivor than the corresponding survivor. The cost savings attributable to the reduced LOS were only 5.4% of the total cost per patient and would probably have been lower considering that the average daily cost was used in the calculation of the costs rather than the actual costs per ICU patient day (which may have been significantly lower in the last few days).^{1,11,22,34}

Limitations
All costs were calculated based on the values of the start year of the study in the current European common currency (euro). For convenience reasons no change in discount or adjustment of price harmonization was made between the two study periods. Although the concepts of cost and expenditure are not identical, in this study they have been used with the same meaning as the amount spent on the running of the ICU. Finally, the cost calculation of the diagnostic examinations, was based on charges taken of the Greek National Agency for Health Services’ (NAHS) list of applicable compensation prices based on a national agreement established by a Greek law in 2015.^{35}

CONCLUSIONS
The recording and analysis of all cost in the ICU for two consecutive years showed the variation of cost between the two study periods. Cost categories in the first period showed an unexpected dominance of direct-variable costs with direct-fixed costs following. This was reversed in the second period and the changes observed were in the reduction in prices for medicines and materials and in the reduction in staff costs. The severity and presence of multi-resistant microbes and by extension, and duration of mechanical ventilation also appear to have affected the duration of hospitalization and changes in both the immediate and the other cost categories. The differences in cost between survivors and non survivors were mainly attributed to the difference in the amount of medicines and materials used but the overall average cost per patient between these two patient categories was relatively small. The extension of this study by a multifactorial analysis method to several ICUs could identify independent factors for cost variability.

REFERENCES
1. Penner S. Economics and financial management for nurses and nurse leaders. 3rd ed. New York, NY: Springer Publishing Company, LLC; 2017.):638-43
2. Kerlin MP, Cooke CR. Understanding Costs When Seeking Value in Critical Care. Ann Am Thorac Soc. 2015; 12(12):1743-4.
3. The direction of health expenditure to health provider and to health care activities (HC x HP) - SHA 2011 EN (2009 - 2018) [Internet]. Hellenic Statistical Authority. 2015 [cited 1 November 2020]. Available from: https://www.statistics.gr/en/statistics/-/publication/SHE35/
4. Angus DC, Barnato AE, Linde-Zwirble WT, Weissfeld LA, Watson RS, Rickert T, et al. Use of intensive care at the end of life in the United States: an epidemiologic study. Critical care medicine. 2004;32(3):638-43
5. Huynh TN, Kleerup EC, Wiley JF, Savitsky TD, Guse D, Garber BJ, et al. The frequency and cost of treatment
perceived to be futile in critical care. JAMA Intern Med. 2013;173(20):1887-94.

6. Halpern NA, Pastores SM. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Critical care medicine. 2010;38(1):65-71.

7. Tan SS, Rutten FF, van Ieveld BM, et al. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ. 2009; 10:39-45.

8. Wordsworth S, Ludbrook A, Caskey F, Macleod A. Collecting unit cost data in multicentre studies: creating comparable methods. Eur J Health Econ. 2005; 6:38-44.

9. Andersen JS, Drenck NE, Keiding H. [Diagnosis Related Groups in intensive care units--cost model for critically ill patients]. Ugeskr Laeger. 2007; 169(8):727-30.

10. Weiss M, Martin J, Feser U, Schafmayer C, Bauer M. Necessity and problems with case-related costing for intensive care patients. Der Anaesthesist. 2005; 54(3):254-62.

11. Rapoport J, Teres D, Zhao Y, Lemeshow S. Length of stay data as a guide to hospital economic performance for ICU patients. Medical care. 2003; 41(3):386-97.

12. Lefrant JY, Garrigues B, Pribil C, Bardoulat I, Courtial F, Maurel F, et al. The daily cost of ICU patients: A micro-costing study in 23 French Intensive Care Units. Anaesthesia, critical care & pain medicine. 2015; 34(3):151-7.

13. Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H. Definitions and methods of cost assessment: an intensivist’s guide. ESICM section on health research and outcome working group on cost effectiveness. Intensive care medicine. 2002; 28(6):680-5.

14. Graf J, Wagner J, Graf C, Koch KC, Janssens U. Five-year survival, quality of life, and individual costs of 303 consecutive medical intensive care patients--a cost-utility analysis. Critical care medicine. 2005; 33(3):547-55.

15. Smithies M, Bihari D, Chang R. Scoring systems and the measurement of ICU cost effectiveness. Réanimation urgenies. 1994;3:215–21

16. Kosmidis D., Koutsouki S., Lampiri K., Nagy EO, Papai-oannou V, Pneumatikos I, Anastassopoulos G. Design and Implementation of the Intensive Care Unit Quality Management Registry: Monitoring Quality and Cost of an Adult Intensive Care Unit in a Greek State Hospital. Comput Inform Nurs. 2017; 35(11), 582-589.

17. Tan SS, Bakker J, Hoogendoorn ME, Kapila A, Martin J, Pezzi A, et al. Direct cost analysis of intensive care unit stay in four European countries: applying a standardized costing methodology. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2012; 15(1):81-6.

18. Bloomfield E, Divertie GD, Burger CD, et al. A comparison of intensive care unit physician staffing costs at the 3 Mayo Clinic sites. Mayo Clinic Proceedings. 2006; 81(11):1457-1461.

19. Moran JL, Peisach AR, Solomon PJ, Martin J Cost calculation and prediction in adult intensive care: a ground-up utilization study, Anaesthesia and Intensive Care. 2004; 32(6):787-797.

20. Rechner IJ, Lipman J. The costs of caring for patients in a tertiary referral Australian Intensive Care Unit. Anaesthesia and Intensive Care. 2005; 33(4):477-482.

21. Ministry of Health and Social Solidarity. Report on the outcomes of Ministry of Health and its health units, 2011. Athens, Dionikos, March 2012 [in Greek]. In: Economou C, Kaitelidou D, Kentikelenis A, Sissouras A, Maresso A. The impact of the financial crisis on the health system and health in Greece. [Internet]. WHO 2014 [cited 14 May 2020]. Available from: https://www.euro.who.int/__data/assets/pdf_file/0007/266380/The-impact-of-the-financial-crisis-on-the-health-system-and-health-in-Greece.pdf?ua=1

22. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med.
23. Vincent JL, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639-644
24. Jia H, Li W, Hou T, Ma H, Yang Y, Wu A, et al. The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China. Biomed Res Int. 2019; 2019:7634528.
25. Tansarli GS, Karageorgopoulos DE, Kapakselis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013; 11(3):321-31.
26. Adair JG. The Hawthorne effect: A reconsideration of the methodological artifact. Journal of Applied Psychology. 1984; 69(2):334-45.
27. Eurostat. Main GDP aggregates per capita [Internet]. Eurostat. [cited 8 June 2020]. Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=nama_10_pc&lang=en
28. Karabatsou D, Tsironi M, Tsigou E, Boutzouka E, Katsoulas T, Baltopoulos G. Variable cost of ICU care, a micro-costing analysis. Intensive Crit Care Nurs. 2016; 35:66-73.
29. Roberts RR, Frutos PW, Ciavarella GG, Gussow LM, Mensah EK, Kampe LM, Straus HE, Joseph G, Rydman RJ. Distribution of variable vs fixed costs of hospital care. JAMA 1999; 281:644-649.
30. Kerlin MP, Cooke CR. Understanding Costs When Seeking Value in Critical Care. Ann Am Thorac Soc. 2015; 12(12):1743-4.
31. Peter JV, Thomas K, Jeyaseelan L, Yadav B, Sudarsan TI, Christina J, et al. Cost of Intensive Care in India. Int J Technol Assess Health Care. 2016; 32(4):241-5.
32. Kulkarni AP, Divatia JV. A prospective audit of costs of intensive care in cancer patients in India. Indian J Crit Care Med. 2013; 17(5):292-7.
33. Khandelwal, N., Benkeser, D., Coe, N. B., Engelberg, R. A., Teno, J. M., & Curtis, J. R. Patterns of Cost for Patients Dying in the Intensive Care Unit and Implications for Cost Savings of Palliative Care Interventions. Journal of palliative medicine. 2016; 19(11):1171–1178. https://doi.org/10.1089/jpm.2016.0133
34. Kahn JM, Rubenfeld GD, Rohrbach J, Fuchs BD. Cost Savings Attributable to Reductions in Intensive Care Unit Length of Stay for Mechanically Ventilated Patients. Medical Care. 2008; 46(12):1226-33.
35. Greece. Dept. of Health. 2015. Short-Term and Long-Term Control Measures of Prescribing and Execution Laboratories–Examinations. Government Gazette No. B 2816/2015:Annex E 21 Dec.
### Table 1. Main characteristics of study sample.

| Sample Characteristics                   | 1st period          | 2nd period          | Total                  |
|------------------------------------------|---------------------|---------------------|------------------------|
| Patients (N, %)                          | 172 (51.95%)        | 159 (48.04%)        | 331 (100%)             |
| Male (N,%)                               | 125 (72.7%)         | 98 (61.6%)          | 223 (67.4%)            |
| Female (N,%)                             | 47 (32.3%)          | 61 (38.4%)          | 108 (32.6%)            |
| Age (mean, SD)                           | 61.7±16.37          | 59.53±17.67         | 331 (60.66±17.02)      |
| LOS days (mean, SD)                      | 9.53±11.54          | 7.44±7.83           | 7.49±9.94              |
| LOS (days)                               | 1640                | 1183                | 2823                   |
| MV days (mean, SD)                       | 6.31±8.12           | 4.89±5.74           | 5.63±7.1               |
| Pathological patients                    | 73 (42.44%)         | 69 (43.40%)         | 142 (42.90%)           |
| Surgical patients                        | 99 (57.56%)         | 90 (56.60%)         | 189 (57.10%)           |
| Ventilator Utilization Ratio (mean, SD)  | 0.77±0.23           | 0.79±0.23           | 0.78±0.23              |
| APACHE II Score (mean, SD)               | 19.88±7.86          | 20.57±8.02          | 20.20±7.92             |
| APACHE II PDR (mean, SD)                 | 38.00±22.22         | 39.56±22.60         | 38.72±22.36            |
| SAPS II Score (mean, SD)                 | 50.12±17.81         | 49.84±17.96         | 49.98±17.94            |
| SAPS II PDR (mean, SD)                   | 45.95±29.14         | 45.36±29.61         | 45.67±29.30            |
| ISS Score (mean, SD)                     | 24.03±15.46         | 26.80±16.23         | 25.50±15.83            |
| RTS Score (mean, SD)                     | 5.28±1.56           | 5.40±1.53           | 5.34±1.53              |
| Survivors (N, %)                         | 131 (76.16%)        | 115 (72.33%)        | 246 (74.3%)            |
| Non-Survivors (N, %)                     | 41 (23.84%)         | 44 (27.87%)         | 85 (25.7%)             |
| ECPS (Efficiency Cost Per Survivor)      | 9,828.4€            |                     |                       |
| Occupancy rate (%)                       | 74.88%              | 53.99%              | 64.43%                 |
| SMR                                      | 0.6779 (95% CI 0.48–0.95) |          |                       |

LOS=Length Of Stay, MV=Mechanical Ventilation, APACHE II=Acute Physiology And Chronic Health Evaluation II, SAPS= Simplified Acute Physiology Score, ISS=Injury Severity Score, RTS=Revised Trauma Score, SMR= Standardised Mortality Ratio.
**Table 2.** Reasons for patient admission.

| Reasons of admission                        | N. (%)    |
|---------------------------------------------|-----------|
| Respiratory failure                         | 54 (16.3%)|
| Multiple trauma                             | 27 (8.2%) |
| Head injury                                 | 23 (6.9%) |
| Craniotomy, neoplasm                        | 22 (6.6%) |
| Multiple organ dysfunction                   | 20 (6.0%) |
| Craniotomy, ICD/SDH/SAH                      | 18 (5.4%) |
| Craniotomy, head injury                      | 12 (3.6%) |
| Brain Hemorrhage                             | 11 (3.3%) |
| Coma / depressed LOC                         | 10 (3.0%) |
| Situation after cardiac arrest               | 10 (3.0%) |
| Septic shock                                | 9 (2.7%)  |
| Poisoning                                   | 8 (2.4%)  |
| Bronchoscopy under sedation                 | 7 (2.1%)  |
| GI surgery, bleeding                         | 7 (2.1%)  |
| GI surgery, neoplasm                         | 7 (2.1%)  |
| Other                                        | 86 (25.98%)|
Table 3. Cost per component analyses of all categories cost in the 2 study periods. *Training costs were calculated indirectly (from the days of absence of staff on leave) and are not included in the final totals.

| Cost Category | Cost components | (1st period) | (2nd period) | Total (€, %) |
|---------------|----------------|--------------|--------------|-------------|
| **Direct Variable** | | | | |
| Cost1 | Medical care materials | 171987.4 (12.5%) | 91974.0 (8.8%) | 263961.4 (10.92%) |
| Cost2 | Medical imagining (X-ray, echo, U/s, MRI, CT e.t.c) | 6166.8 (0.4%) | 3924.8 (0.4%) | 10091.6 (0.42%) |
| Cost3 | Lab tests (Microbiology, Hematology Biochemistry) | 48976.95 (3.6%) | 32198.42 (3.1%) | 81175.37 (3.36%) |
| Cost4 | Medications - Fluids (Including TPN) | 342172.6 (25.0%) | 196356.1 (18.7%) | 538528.7 (22.27%) |
| Cost5 | Enteral feeding. (Including per os diet) | 2462.0 (0.2%) | 1647.0 (0.2%) | 41090.0 (0.17%) |
| Subtotal of Direct Variable | | 571765.75 (41.7%) | 326100.32 (31.1%) | 897866.07 (37.14%) |
| **Direct Fixed** | | | | |
| Cost6 | Labor (ICU specialists) | 198561.0 (14.5%) | 169775.1 (16.2%) | 368336.1 (15.23%) |
| Cost7 | Labor (ICU nursing staff) | 310473.0 (22.7%) | 283368.9 (27.1%) | 593841.9 (24.56%) |
| Cost8,9,10 | Labor (ICU specialists) | 38259.0 (2.8%) | 35170.5 (3.4%) | 73429.5 (3.04%) |
| Cost11 | Investment in new equipment (medical) | 0 (0.0%) | 4650.0 (0.4%) | 4650.0 (0.19%) |
| Cost12 | Equipment maintenance (medical) | 6226.2 (0.5%) | 2584.9 (0.2%) | 8811.1 (0.36%) |
| Cost12 | Staff continuing education* | 331,2 | 1135,6 | 1466,8 |
| Subtotal of Direct Fixed | | 553519,2 (40.4%) | 495549,4 (47.3%) | 1049068,6 (43.39%) |
| **Indirect Variable** | | | | |
| Cost13-18 | Miscellaneous, non-medical disposables (included, cleaning materials, clothing, technical materials, maintenance of common – non medical, stationary) | 21116.43 (1.5%) | 19340.39 (1.8%) | 40456.82 (1.67%) |
| Cost19 | Miscellaneous, medical disposable materials (including antiseptics, – disinfection agents etc.) | 1480.3 (0.1%) | 2647.29 (0.3%) | 4127.59 (0.17%) |
| Cost21 | Other miscellaneous, non-medical disposables for common use | 305.1 (0.02%) | 321.09 (0.02%) | 626.19 (0.03%) |
| Subtotal of Indirect Variable | | 22901,83 (1.7%) | 22308.77 (2.1%) | 45210.6 (1.87%) |
| **Indirect Fixed** | | | | |
| Cost23 | ROI (Return Of Investment) for ICU | 69270.8 (5.1%) | 69413.5 (6.6%) | 138684.3 (5.74%) |

Kosmidis et al. 50  https://ejournals.epublishing.ekt.gr/index.php/HealthResJ
Cost24 | Hospital Supporting Services (administrative, technical, hospital security etc) | 45348.8 (3.3%) | 50986.5 (4.9%) | 96335.3 (3.98%) |
Cost25 | Heating expenses | 25419.1 (1.9%) | 18256.6 (1.7%) | 43675.7 (1.81%) |
Cost26 | ICU maintenance (Hotel infrastructure) | 24067.4 (1.8%) | 17309.3 (1.7%) | 41376.7 (1.71%) |
Cost27 | Cleaning services | 35843.0 (2.6%) | 27774.8 (2.7%) | 63617.8 (2.63%) |
Cost28 | Electricity expenses | 19988.0 (1.5%) | 16666.0 (1.6%) | 36654.0 (1.52%) |
Cost29 | Water expenses | 2296.0 (0.2%) | 3003.2 (0.3%) | 5299.2 (0.22%) |

| Subtotal of Indirect Fixed | 222233.1 (16.2%) | 203409.9 (19.4%) | 425643.0 (17.60%) |

| TOTAL | 1370420 | 1047368 | 2417788.0 (100.00%) |

Table 4. Category and total costs in 2 study periods.

## Table 5. Mean daily cost and mean total cost per patient for each combined category in the 2 study periods.

| Cost category | 1st period (€) | 2nd period (€) | Total (€) |
|---------------|----------------|----------------|-----------|
| Sum of Direct cost | 1125285.0 (82.1%) | 821649.7 (78.4%) | 1946934.7 (80.5%) |
| Sum of Indirect cost | 245134.9 (17.9%) | 225718.7 (21.6%) | 470853.6 (19.5%) |
| Sum of Variable cost | 594667.6 (43.4%) | 348409.1 (33.3%) | 943076.7 (39.0%) |
| Sum of Fixed cost | 775752.3 (56.6%) | 698959.3 (66.7%) | 1474711.6 (61.0%) |

| Cost category | Mean daily cost / Mean total patient cost (€) | Mean daily cost / Mean total patient cost (€) |
|---------------|---------------------------------------------|---------------------------------------------|
| Direct-Variable | 348.64 / 3324.2 | 275.66 / 2050.9 |
| Direct-Fixed | 337.51 / 3218.1 | 418.89 / 3116.7 |
| Indirect-Variable | 13.96 / 133.2 | 18.86 / 140.3 |
| Indirect-Fixed | 135.51 / 1292.1 | 171.94 / 1279.3 |
| Total Sum | 835.62 / 7967.6 | 885.35 / 6587.2 |
Graph 1. Category cost rate changes between the two periods of study.

Table 6. Mean monthly and total gross salaries for each staff category in ICU (€). *Mean staff units per year.

| Staff category         | 1st period | 2nd period |
|------------------------|------------|------------|
|                        | N*         | Mean monthly gross salary (€) | Total gross salary (€) | N*         | Mean monthly gross salary (€) | Total gross salary (€) |
| Nurses                 | 18.0       | 17248.5 (20.9%) | 310473.0 (56.7%) | 16.3       | 16448.2 (10.2%) | 268648.8 (56.7%) |
| Physicians             | 5.0        | 39712.2 (48.1%) | 198561.0 (36.3%) | 4.0        | 42443.8 (49.5%) | 169775.1 (35.8%) |
| Non-medical staff      | 1.3        | 17167.2 (20.8%) | 21459.0 (3.9%) | 1.0        | 18370.5 (21.4%) | 18370.5 (3.9%) |
| Housekeeping           | 2.0        | 8400.0 (10.2%) | 16800.0 (3.1%) | 2.0        | 8400.0 (9.8%) | 16800.0 (3.5%) |
| **Total**              | 26.3       | 82527.9     | 547293.0       | 23.3       | 85662.5      | 473594.4      |
Table 7. Total, mean daily and mean total patient cost analysis for each combined category cost of survivors and non survivors (€).

| Cost categories       | Total cost | Mean daily cost | Mean cost per patient |
|-----------------------|------------|-----------------|-----------------------|
|                       | Survivors  | Non-Survivors   | Survivors  | Non-Survivors | Survivors  | Non-Survivors |
| Direct-Variable       | 667296.2   | 242352.72       | 302.4      | 370.0         | 2664.7     | 2851.2        |
| Direct-Fixed          | 805660.9   | 243407.7        | 359.6      | 411.3         | 3275.0     | 2863.6        |
| Indirect-Variable     | 34720.7    | 10489.9         | 15.5       | 17.7          | 141.1      | 123.4         |
| Indirect-Fixed        | 326884.2   | 98758.8         | 145.9      | 166.9         | 1328.8     | 1161.9        |

Graph 2. Cost category rates of survivors and non survivors (%).
**Graph 3.** Direct-variable cost components for survivors and non-survivors: Mean cost per patient (€).

![Direct variable cost components for survivors and non-survivors: Mean cost per patient](chart.png)